CHIEF INVESTIGATOR

A/Prof Niall Corcoran, Clinician Researcher, Department of Surgery, The University of Melbourne

COLLABORATING INSTITUTIONS

TYPE/ROLE

University of MelbourneLEAD INSTITUTE
Walter and Eliza Hall Institute of Medical ResearchCOLLABORATOR
Cambridge University HospitalCOLLABORATOR
Cancer Sciences, University of ManchesterCOLLABORATOR
Dana-Farber Cancer InstituteCOLLABORATOR
Department of Medical Oncology, Monash HealthCOLLABORATOR
Ontario Institute for Cancer ResearchCOLLABORATOR
School of Medicine, Faculty of Health at Deakin UniversityCOLLABORATOR
School of Medicine, University of SydneyCOLLABORATOR
South Australian Health & Medical Research InsituteCOLLABORATOR
The Institute of Cancer ResearchCOLLABORATOR
South Australian Health & Medical Research InsituteCOLLABORATOR
Peter MacCallum Cancer CentreCOLLABORATOR
South West Warrnambool HospitalCOLLABORATOR
La Trobe UniversityCOLLABORATOR

GRANT

3 year (2019-2022) $4m grant from the Prostate Cancer Research Alliance, an Australian Government and Movember Foundation Collaboration

SHARE ON SOCIAL MEDIA

tweet linkedin email

This research program aims to:

  1. Develop a tissue and blood test that will predict the future risk of progression in men with prostate cancer at the time of diagnosis.
  2. Develop new ‘curative’ treatments in patients with high risk disease, starting with two clinical studies using novel agents to investigate if treatment effects can be improved.
  3. Develop new tests for DNA markers that predict how tumours will respond to treatment and using those results to help individualise patient treatment according to their specific tumour type to maximise treatment effect.

Danny Park, Bernie Pope and Chol Hee Jung are all working on the genomic aspects of this project.

October 2020 update from the VCCC

Cancer research embraces a shared vision | Victorian Comprehensive Cancer Centre

Learning that you have cancer can be a confronting and frightening experience, and the variation in prostate cancer treatment options can be particularly confusing for men, their families, and carers. VCCC consumers are assisting researchers to understand the impacts of a diagnosis on those affected and how tests and treatments can be improved.

Consumer advisors with direct experience with prostate cancer, long and successful commercial careers, and life and family experience have proved to be a genuine asset to the PRECEPT project team, including Professor Maarten IJzerman. The way in which consumers have been included in the study development provides a good model for others.

The ProstatE CancEr Prognosis and Treatment project (PRECEPT) involves genomics, immunotherapy, and health services research to establish genomic biomarker-based tests for shared decision-making in treatment. Collaborators have set out to develop a tissue and blood test that will predict the future risk of progression in men with prostate cancer at the time of diagnosis; new curative treatments in patients with high-risk disease; and new tests that will predict how patients will respond to treatment. Read more.

Project members

Dr Paul Boutros

Prof Robert Bristow

Dr Margaret Centenera

A/Prof Ian Collins

Prof Rosalind Eeles

Prof Vanessa Hayes

Prof Chris Hovens

Prof Maarten ljzerman

Prof Anthony Papenfuss

Dr Belinda Parker

A/Prof Daniel Park

A/Prof Bernard Pope

Dr Chris Sweeney

Dr Ben Tran

Dr Anis Hamid

Dr Ben Thomas

Dr Edmond Kwan